Ceftriaxone for Post-Treatment Lyme Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ceftriaxone for Post-Treatment Lyme Disease — Stella

Recruiting

Back to Post-Treatment Lyme Disease Syndrome trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Hackensack University Medical Center, Hackensack, New Jersey

Key details

Phase

Early testing / Safety & dosing

Sponsor

Hackensack Meridian Health

Collaborators

Columbia Clinical Trials Network for Lyme and Other Tick-Borne Diseases

Enrollment target

~20 participants

Started

May 2026

Primary completion

December 2027

Age range

18 Years – 75 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov